{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:44:47Z","timestamp":1788893087156,"version":"build-2803163510"},"reference-count":51,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel drugs are needed to increase treatment response in children with high-risk T-cell acute lymphoblastic leukemia (T-ALL). Following up on our previous report on the activation of the MAP2K7-JNK pathway in pediatric T-ALL, here we demonstrate that OTSSP167, recently shown to inhibit MAP2K7, has antileukemic capacity in T-ALL. OTSSP167 exhibited dose-dependent cytotoxicity against a panel of T-ALL cell lines with IC50 in the nanomolar range (10-50 nM). OTSSP167 induces apoptosis and cell cycle arrest in T-ALL cell lines, associated at least partially with the inhibition of MAP2K7 kinase activity and lower activation of its downstream substrate, JNK. Other leukemic T-cell survival pathways, such as mTOR and NOTCH1 were also inhibited. Daily intraperitoneal administration of 10 mg\/kg OTSSP167 was well tolerated, with mice showing no hematological toxicity, and effective at reducing the expansion of human T-ALL cells in a cell-based xenograft model. The same dosage of OTSSP167 efficiently controlled the leukemia burden in the blood, bone marrow, and spleen of 3 patient-derived xenografts, which resulted in prolonged survival. OTSSP167 exhibited synergistic interactions when combined with dexamethasone, L-asparaginase, vincristine, and etoposide. Our findings reveal novel antileukemic properties of OTSSP167 in T-ALL and support the use of OTSSP167 as an adjuvant drug to increase treatment response and reduce relapses in pediatric T-ALL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008548","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T13:45:39Z","timestamp":1668779139000},"page":"422-435","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-2513","authenticated-orcid":false,"given":"Cory Seth","family":"Bridges","sequence":"first","affiliation":[{"name":"1Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Puppi","sequence":"additional","affiliation":[{"name":"1Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8195","authenticated-orcid":false,"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-617X","authenticated-orcid":false,"given":"H. Daniel","family":"Lacorazza","sequence":"additional","affiliation":[{"name":"1Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"issue":"9617","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"issue":"36","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"950","DOI":"10.15585\/mmwr.mm6636a3","article-title":"Rates and trends of pediatric acute lymphoblastic leukemia - United States, 2001-2014","volume":"66","author":"Siegel","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"7696","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"issue":"9","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-12-0383","article-title":"Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance","volume":"19","author":"Pritchard","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/leu.2016.339","article-title":"Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway","volume":"31","author":"Shen","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","article-title":"Discovery of potent and selective covalent inhibitors of JNK","volume":"19","author":"Zhang","year":"2012","journal-title":"Chem Biol"},{"issue":"24","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1073\/pnas.251194298","article-title":"SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase","volume":"98","author":"Bennett","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrd1132","article-title":"Targeting JNK for therapeutic benefit: from junk to gold?","volume":"2","author":"Manning","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bmcl.2014.12.011","article-title":"5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner","volume":"25","author":"Sogabe","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"issue":"18","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.18632\/oncotarget.28040","article-title":"Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia","volume":"12","author":"Chen","year":"2021","journal-title":"Oncotarget"},{"issue":"12","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.18632\/oncotarget.790","article-title":"Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer","volume":"3","author":"Chung","year":"2012","journal-title":"Oncotarget"},{"issue":"41","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-018-0333-x","article-title":"Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"issue":"7","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1210\/en.2018-00310","article-title":"Elucidating the role of the maternal embryonic leucine zipper kinase in adrenocortical carcinoma","volume":"159","author":"Kiseljak-Vassiliades","year":"2018","journal-title":"Endocrinology"},{"issue":"22","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1158\/1078-0432.CCR-18-0924","article-title":"MELK inhibition in diffuse intrinsic pontine glioma","volume":"24","author":"Meel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/neuonc\/noz151","article-title":"MEK\/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid\/rhabdoid tumors","volume":"22","author":"Meel","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10565-018-9435-z","article-title":"A\u00a0novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis","volume":"35","author":"Okur","year":"2019","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12964-019-0446-z","article-title":"Targeting PKCiota-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma","volume":"17","author":"Ito","year":"2019","journal-title":"Cell Commun Signal"},{"issue":"12","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-019-0249-x","article-title":"Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma","volume":"9","author":"Maes","year":"2019","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.chembiol.2020.07.014","article-title":"Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and diverse targeting opportunities","volume":"27","author":"Schroder","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/ncomms4887","article-title":"A\u00a0pan-cancer proteomic perspective on The Cancer Genome Atlas","volume":"5","author":"Akbani","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/jcmm.14878","article-title":"Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1\/S cell cycle arrest via the ATM\/CHK2\/p53 pathway","volume":"24","author":"Chen","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"8","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1074\/jbc.RA119.011083","article-title":"Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells","volume":"295","author":"McDonald","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"5694","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"issue":"9","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2016-09-692582","article-title":"The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia","volume":"129","author":"Sanchez-Martin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023021422370331700_","first-page":"99","article-title":"Combination effect of Notch1 and PI3K\/AKT\/mTOR signaling pathways inhibitors on T-ALL cell lines","volume":"14","author":"Khoshamooz","year":"2020","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"18","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13256-021-02771-z","article-title":"Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed\/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports","volume":"15","author":"Yuda","year":"2021","journal-title":"J\u00a0Med Case Rep"},{"issue":"10","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat Med"},{"issue":"8","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2014.89","article-title":"Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia","volume":"28","author":"Kontro","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"issue":"12","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1038\/s41375-021-01291-5","article-title":"MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance","volume":"35","author":"van der Zwet","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)00116-1","article-title":"Signal transduction by the JNK group of MAP kinases","volume":"103","author":"Davis","year":"2000","journal-title":"Cell"},{"issue":"8","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4161\/cc.28654","article-title":"MKK7 and ARF: new players in the DNA damage response scenery","volume":"13","author":"Kotsinas","year":"2014","journal-title":"Cell Cycle"},{"issue":"3","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.molcel.2005.04.001","article-title":"Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases","volume":"18","author":"Takekawa","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2017.09.025","article-title":"High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7","volume":"493","author":"Kinoshita","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"48","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran","year":"2008","journal-title":"Oncogene"},{"issue":"6476","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/369156a0","article-title":"The stress-activated protein kinase subfamily of c-Jun kinases","volume":"369","author":"Kyriakis","year":"1994","journal-title":"Nature"},{"issue":"12","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1535-7163.MCT-09-0408","article-title":"Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells","volume":"8","author":"Cui","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ncb1098","article-title":"MKK7 couples stress signalling to G2\/M cell-cycle progression and cellular senescence","volume":"6","author":"Wada","year":"2004","journal-title":"Nat Cell Biol"},{"issue":"9","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/ijc.32321","article-title":"MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"issue":"4","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/path.2194","article-title":"Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia","volume":"212","author":"Lotan","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"2023021422370331700_","first-page":"2639","article-title":"miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7","volume":"9","author":"Hong","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11033-014-3834-x","article-title":"Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer","volume":"42","author":"Zubor","year":"2015","journal-title":"Mol Biol Rep"},{"issue":"1","key":"2023021422370331700_","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2013-03-491092","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2013","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/422\/2033322\/blooda_adv-2022-008548-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/422\/2033322\/blooda_adv-2022-008548-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T21:46:18Z","timestamp":1678657578000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/422\/493278\/Antileukemic-properties-of-the-kinase-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008548","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}